TDMS Study 05044-01 Pathology Tables
NTP STATISTICAL ANALYSIS OF PRIMARY TUMORS REPORT: PEIRPT08
LAB: Battelle Columbus 4-VINYL-1-CYCLOHEXENE DIEPOXIDE DATE: 09/06/94
EXPERIMENT: 05044 TEST: 01 TIME: 11:48:23
TEST TYPE: CHRONIC CAGES FROM 0000 TO LAST CAGE PAGE: 1
CONT: N01-CP-95653 ROUTE: DERMAL,SOLUTION NTP C#: 60139A
PATHOLOGIST: S. GRUMBEIN S. EUSTIS CAS: 106-87-6
------------------------------------------------------------------------------------------------------------------------------------
REASONS FOR REMOVAL: ALL
REMOVAL DATE RANGE: ALL
TREATMENT GROUPS: INCLUDE ALL
NTP STATISTICAL ANALYSIS OF PRIMARY TUMORS REPORT: PEIRPT08
LAB: Battelle Columbus 4-VINYL-1-CYCLOHEXENE DIEPOXIDE DATE: 09/06/94
EXPERIMENT: 05044 TEST: 01 TIME: 11:48:23
TEST TYPE: CHRONIC CAGES FROM 0000 TO LAST CAGE
CONT: N01-CP-95653 ROUTE: DERMAL,SOLUTION NTP C#: 60139A
PATHOLOGIST: S. GRUMBEIN S. EUSTIS CAS: 106-87-6
RATS(FISCHER344)
----------------------------
FOR ALL DOSES THE TUMOR RATES IN THE FOLLOWING TISSUES/ORGANS ARE BASED ON NUMBER OF TISSUES EXAMINED.
IN OTHER TISSUES/ORGANS, RATES ARE BASED ON NUMBER OF ANIMALS NECROPSIED.
----------------
Adrenal Gland
Bone Marrow
Brain
Clitoral Gland
Epididymis
Heart
Islets, Pancreatic
Kidney
Liver
Lung
Nose
Ovary
Pancreas
Parathyroid Gland
Pituitary Gland
Preputial Gland
Prostate
Salivary Glands
Spleen
Testes
Thymus
Thyroid Gland
Urinary Bladder
NTP STATISTICAL ANALYSIS OF PRIMARY TUMORS REPORT: PEIRPT08
LAB: Battelle Columbus 4-VINYL-1-CYCLOHEXENE DIEPOXIDE DATE: 09/06/94
EXPERIMENT: 05044 TEST: 01 TIME: 11:48:23
TEST TYPE: CHRONIC CAGES FROM 0000 TO LAST CAGE
CONT: N01-CP-95653 ROUTE: DERMAL,SOLUTION NTP C#: 60139A
PATHOLOGIST: S. GRUMBEIN S. EUSTIS CAS: 106-87-6
SUMMARY OF STATISTICALLY SIGNIFICANT (P<=.05) RESULTS
IN THE ANALYSIS OF THE STUDY OF 4-VINYL-1-CYCLOHEXENE DIEPOXIDE
====================================================================================================
MALE RATS
-------------
ORGAN MORPHOLOGY
------- ------------
Adrenal Medulla Pheochromocytoma Benign
Pheochromocytoma: Benign, Complex, Malignant, NOS
Skin Basal Cell Adenoma
Squamous Cell Carcinoma
Squamous Cell Carcinoma, Papilloma Squamous, or Papilloma
Squamous Cell Papilloma
Trichoepithelioma, Basal Cell Carcinoma, or Basal Cell Adenoma
Trichoepithelioma, Kertatocanthoma, Squamous Cell Carcinoma,
Basal Cell Carcinoma or Adenoma, Papilloma Squamous, or Papilloma
Thyroid Gland: C-Cell Carcinoma or Adenoma
All Organs Benign Tumors
Malignant Tumors
====================================================================================================
FEMALE RATS
-------------
ORGAN MORPHOLOGY
------- ------------
Mammary Gland Fibroadenoma
Fibroma, Fibroadenoma, Carcinoma, or Adenoma
Skin Basal Cell Carcinoma
Squamous Cell Carcinoma
Squamous Cell Carcinoma, Papilloma Squamous, or Papilloma
Trichoepithelioma, Basal Cell Carcinoma, or Basal Cell Adenoma
Trichoepithelioma, Kertatocanthoma, Squamous Cell Carcinoma,
Basal Cell Carcinoma or Adenoma, Papilloma Squamous, or Papilloma
Thyroid Gland: C-Cell Adenoma
Carcinoma or Adenoma
Uterus Polyp Stromal
Sarcoma Stromal or Polyp Stromal
All Organs Malignant Tumors
Malignant and Benign Tumors
====================================================================================================
DATE: 09/06/94 EXPERIMENT: 05044 TEST: 01 PAGE 1
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN RATS(FISCHER344) -- 4-VINYL-1-CYCLOHEXENE DIEPOXIDE
TERMINAL SACRIFICE AT 107 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | 0 MG/ML 50 MG/ML 100 MG/ | 0 MG/ML 50 MG/ML 100 MG/ |
| | ML | ML |
|=================================================================================================================================|
| |
|Adrenal Medulla |
| Pheochromocytoma Benign |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 8/50 (16%) 15/50 (30%) 0/50 (0%) | 2/50 (4%) 3/48 (6%) 1/50 (2%) |
|ADJUSTED (b) | 46.1% 64.7% 0.0% | 6.3% 13.0% 4.3% |
|TERMINAL (d) | 1/7 (14%) 2/8 (25%) 0/4 (0%) | 1/27 (4%) 3/23 (13%) 0/15 (0%) |
|FIRST INCIDENCE (DAYS) | 571 569 --- | 698 743 (T) 684 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.065N P=0.239 P=0.020N* | P=0.568 P=0.406 P=0.711N |
|INCIDENTAL TUMOR | P=0.015N* P=0.104 P=0.005N** | P=0.513N P=0.374 P=0.519N |
|LOGISTIC REGRESSION | P=0.021N* P=0.112 P=0.006N** | P=0.577N P=0.379 P=0.594N |
|COCHRAN-ARMITAGE | P=0.019N* | P=0.400N |
|FISHER EXACT | P=0.077 P=0.003N** | P=0.480 P=0.500N |
|=================================================================================================================================|
| |
|Adrenal Medulla |
| Pheochromocytoma Malignant |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 0/50 (0%) 0/50 (0%) 2/50 (4%) | 1/50 (2%) 0/48 (0%) 0/50 (0%) |
|ADJUSTED (b) | 0.0% 0.0% 7.8% | 3.7% 0.0% 0.0% |
|TERMINAL (d) | 0/7 (0%) 0/8 (0%) 0/4 (0%) | 1/27 (4%) 0/23 (0%) 0/15 (0%) |
|FIRST INCIDENCE (DAYS) | --- --- 350 | 743 (T) --- --- |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.079 (e) P=0.209 | P=0.343N P=0.532N P=0.617N |
|INCIDENTAL TUMOR | P=0.175 (e) P=0.487 | P=0.343N P=0.532N P=0.617N |
|LOGISTIC REGRESSION | P=0.098 (e) P=0.288 | P=0.343N P=0.532N P=0.617N |
|COCHRAN-ARMITAGE | P=0.095 | P=0.271N |
|FISHER EXACT | (e) P=0.247 | P=0.510N P=0.500N |
|=================================================================================================================================|
DATE: 09/06/94 EXPERIMENT: 05044 TEST: 01 PAGE 2
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN RATS(FISCHER344) -- 4-VINYL-1-CYCLOHEXENE DIEPOXIDE
TERMINAL SACRIFICE AT 107 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | 0 MG/ML 50 MG/ML 100 MG/ | 0 MG/ML 50 MG/ML 100 MG/ |
| | ML | ML |
|=================================================================================================================================|
| |
|Adrenal Medulla |
| Pheochromocytoma: Benign, Complex, Malignant, NOS |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 8/50 (16%) 15/50 (30%) 2/50 (4%) | 3/50 (6%) 3/48 (6%) 1/50 (2%) |
|ADJUSTED (b) | 46.1% 64.7% 7.8% | 9.9% 13.0% 4.3% |
|TERMINAL (d) | 1/7 (14%) 2/8 (25%) 0/4 (0%) | 2/27 (7%) 3/23 (13%) 0/15 (0%) |
|FIRST INCIDENCE (DAYS) | 571 569 350 | 698 743 (T) 684 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.187N P=0.239 P=0.126N | P=0.472N P=0.569 P=0.542N |
|INCIDENTAL TUMOR | P=0.042N* P=0.104 P=0.018N* | P=0.362N P=0.540 P=0.371N |
|LOGISTIC REGRESSION | P=0.080N P=0.112 P=0.052N | P=0.419N P=0.535 P=0.431N |
|COCHRAN-ARMITAGE | P=0.070N | P=0.240N |
|FISHER EXACT | P=0.077 P=0.046N* | P=0.641 P=0.309N |
|=================================================================================================================================|
| |
|Clitoral/Preputial Gland |
| Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 0/49 (0%) 3/49 (6%) 1/50 (2%) | 2/45 (4%) 7/50 (14%) 3/49 (6%) |
|ADJUSTED (b) | 0.0% 14.0% 2.6% | 8.0% 25.7% 12.2% |
|TERMINAL (d) | 0/6 (0%) 0/8 (0%) 0/4 (0%) | 2/25 (8%) 4/23 (17%) 0/14 (0%) |
|FIRST INCIDENCE (DAYS) | --- 538 568 | 743 (T) 534 675 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.349 P=0.158 P=0.511 | P=0.174 P=0.061 P=0.283 |
|INCIDENTAL TUMOR | P=0.393 P=0.104 P=0.569 | P=0.426 P=0.055 P=0.475 |
|LOGISTIC REGRESSION | P=0.385 P=0.121 P=0.519 | P=0.305 P=0.059 P=0.411 |
|COCHRAN-ARMITAGE | P=0.385 | P=0.475 |
|FISHER EXACT | P=0.121 P=0.505 | P=0.107 P=0.541 |
|=================================================================================================================================|
DATE: 09/06/94 EXPERIMENT: 05044 TEST: 01 PAGE 3
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN RATS(FISCHER344) -- 4-VINYL-1-CYCLOHEXENE DIEPOXIDE
TERMINAL SACRIFICE AT 107 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | 0 MG/ML 50 MG/ML 100 MG/ | 0 MG/ML 50 MG/ML 100 MG/ |
| | ML | ML |
|=================================================================================================================================|
| |
|Clitoral/Preputial Gland |
| Carcinoma or Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 0/49 (0%) 3/49 (6%) 1/50 (2%) | 3/45 (7%) 7/50 (14%) 3/49 (6%) |
|ADJUSTED (b) | 0.0% 14.0% 2.6% | 10.6% 25.7% 12.2% |
|TERMINAL (d) | 0/6 (0%) 0/8 (0%) 0/4 (0%) | 2/25 (8%) 4/23 (17%) 0/14 (0%) |
|FIRST INCIDENCE (DAYS) | --- 538 568 | 698 534 675 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.349 P=0.158 P=0.511 | P=0.263 P=0.116 P=0.395 |
|INCIDENTAL TUMOR | P=0.393 P=0.104 P=0.569 | P=0.555N P=0.095 P=0.667N |
|LOGISTIC REGRESSION | P=0.385 P=0.121 P=0.519 | P=0.447 P=0.127 P=0.586 |
|COCHRAN-ARMITAGE | P=0.385 | P=0.520N |
|FISHER EXACT | P=0.121 P=0.505 | P=0.205 P=0.620N |
|=================================================================================================================================|
| |
|Clitoral/Preputial Gland |
| Squamous Cell Papilloma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 0/49 (0%) 2/49 (4%) 0/50 (0%) | 0/45 (0%) 0/50 (0%) 0/49 (0%) |
|ADJUSTED (b) | 0.0% 8.9% 0.0% | 0.0% 0.0% 0.0% |
|TERMINAL (d) | 0/6 (0%) 0/8 (0%) 0/4 (0%) | 0/25 (0%) 0/23 (0%) 0/14 (0%) |
|FIRST INCIDENCE (DAYS) | --- 609 --- | --- --- --- |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.650 P=0.306 (e) | (e) (e) (e) |
|INCIDENTAL TUMOR | P=0.627N P=0.204 (e) | (e) (e) (e) |
|LOGISTIC REGRESSION | P=0.669 P=0.245 (e) | (e) (e) (e) |
|COCHRAN-ARMITAGE | P=0.664N | (e) |
|FISHER EXACT | P=0.247 (e) | (e) (e) |
|=================================================================================================================================|
DATE: 09/06/94 EXPERIMENT: 05044 TEST: 01 PAGE 4
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN RATS(FISCHER344) -- 4-VINYL-1-CYCLOHEXENE DIEPOXIDE
TERMINAL SACRIFICE AT 107 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | 0 MG/ML 50 MG/ML 100 MG/ | 0 MG/ML 50 MG/ML 100 MG/ |
| | ML | ML |
|=================================================================================================================================|
| |
|Islets, Pancreatic |
| Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 1/50 (2%) 2/50 (4%) 3/46 (7%) | 0/48 (0%) 1/48 (2%) 1/48 (2%) |
|ADJUSTED (b) | 2.5% 7.2% 16.7% | 0.0% 4.3% 6.7% |
|TERMINAL (d) | 0/7 (0%) 0/8 (0%) 0/4 (0%) | 0/27 (0%) 1/23 (4%) 1/15 (7%) |
|FIRST INCIDENCE (DAYS) | 548 642 591 | --- 743 (T) 743 (T) |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.188 P=0.572 P=0.287 | P=0.214 P=0.468 P=0.383 |
|INCIDENTAL TUMOR | P=0.286 P=0.425 P=0.370 | P=0.214 P=0.468 P=0.383 |
|LOGISTIC REGRESSION | P=0.196 P=0.500 P=0.276 | P=0.214 P=0.468 P=0.383 |
|COCHRAN-ARMITAGE | P=0.196 | P=0.331 |
|FISHER EXACT | P=0.500 P=0.278 | P=0.500 P=0.500 |
|=================================================================================================================================|
| |
|Islets, Pancreatic |
| Carcinoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 0/50 (0%) 2/50 (4%) 0/46 (0%) | 0/48 (0%) 0/48 (0%) 0/48 (0%) |
|ADJUSTED (b) | 0.0% 20.5% 0.0% | 0.0% 0.0% 0.0% |
|TERMINAL (d) | 0/7 (0%) 1/8 (13%) 0/4 (0%) | 0/27 (0%) 0/23 (0%) 0/15 (0%) |
|FIRST INCIDENCE (DAYS) | --- 730 --- | --- --- --- |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.569 P=0.277 (e) | (e) (e) (e) |
|INCIDENTAL TUMOR | P=0.618 P=0.280 (e) | (e) (e) (e) |
|LOGISTIC REGRESSION | P=0.605 P=0.284 (e) | (e) (e) (e) |
|COCHRAN-ARMITAGE | P=0.652 | (e) |
|FISHER EXACT | P=0.247 (e) | (e) (e) |
|=================================================================================================================================|
DATE: 09/06/94 EXPERIMENT: 05044 TEST: 01 PAGE 5
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN RATS(FISCHER344) -- 4-VINYL-1-CYCLOHEXENE DIEPOXIDE
TERMINAL SACRIFICE AT 107 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | 0 MG/ML 50 MG/ML 100 MG/ | 0 MG/ML 50 MG/ML 100 MG/ |
| | ML | ML |
|=================================================================================================================================|
| |
|Islets, Pancreatic |
| Carcinoma or Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 1/50 (2%) 4/50 (8%) 3/46 (7%) | 0/48 (0%) 1/48 (2%) 1/48 (2%) |
|ADJUSTED (b) | 2.5% 26.2% 16.7% | 0.0% 4.3% 6.7% |
|TERMINAL (d) | 0/7 (0%) 1/8 (13%) 0/4 (0%) | 0/27 (0%) 1/23 (4%) 1/15 (7%) |
|FIRST INCIDENCE (DAYS) | 548 642 591 | --- 743 (T) 743 (T) |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.178 P=0.246 P=0.287 | P=0.214 P=0.468 P=0.383 |
|INCIDENTAL TUMOR | P=0.282 P=0.163 P=0.370 | P=0.214 P=0.468 P=0.383 |
|LOGISTIC REGRESSION | P=0.216 P=0.195 P=0.276 | P=0.214 P=0.468 P=0.383 |
|COCHRAN-ARMITAGE | P=0.220 | P=0.331 |
|FISHER EXACT | P=0.181 P=0.278 | P=0.500 P=0.500 |
|=================================================================================================================================|
| |
|Mammary Gland |
| Carcinoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 1/50 (2%) 2/50 (4%) 0/50 (0%) | 2/50 (4%) 3/50 (6%) 1/50 (2%) |
|ADJUSTED (b) | 14.3% 25.0% 0.0% | 7.4% 11.5% 3.2% |
|TERMINAL (d) | 1/7 (14%) 2/8 (25%) 0/4 (0%) | 2/27 (7%) 2/23 (9%) 0/15 (0%) |
|FIRST INCIDENCE (DAYS) | 743 (T) 743 (T) --- | 743 (T) 625 648 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.491N P=0.550 P=0.612N | P=0.583N P=0.417 P=0.660N |
|INCIDENTAL TUMOR | P=0.491N P=0.550 P=0.612N | P=0.518N P=0.508 P=0.610N |
|LOGISTIC REGRESSION | P=0.491N P=0.550 P=0.612N | P=0.506N P=0.414 P=0.604N |
|COCHRAN-ARMITAGE | P=0.360N | P=0.399N |
|FISHER EXACT | P=0.500 P=0.500N | P=0.500 P=0.500N |
|=================================================================================================================================|
DATE: 09/06/94 EXPERIMENT: 05044 TEST: 01 PAGE 6
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN RATS(FISCHER344) -- 4-VINYL-1-CYCLOHEXENE DIEPOXIDE
TERMINAL SACRIFICE AT 107 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | 0 MG/ML 50 MG/ML 100 MG/ | 0 MG/ML 50 MG/ML 100 MG/ |
| | ML | ML |
|=================================================================================================================================|
| |
|Mammary Gland |
| Fibroadenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 1/50 (2%) 1/50 (2%) 1/50 (2%) | 20/50 (40%) 11/50 (22%) 8/50 (16%) |
|ADJUSTED (b) | 5.9% 8.3% 7.7% | 54.4% 37.6% 40.2% |
|TERMINAL (d) | 0/7 (0%) 0/8 (0%) 0/4 (0%) | 12/27 (44%) 7/23 (30%) 4/15 (27%) |
|FIRST INCIDENCE (DAYS) | 682 722 684 | 425 542 675 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.587 P=0.710N P=0.722 | P=0.117N P=0.140N P=0.191N |
|INCIDENTAL TUMOR | P=0.631 P=0.713N P=0.750 | P=0.014N* P=0.025N* P=0.026N* |
|LOGISTIC REGRESSION | P=0.610 P=0.726N P=0.738 | P=0.014N* P=0.057N P=0.023N* |
|COCHRAN-ARMITAGE | P=0.640 | P=0.004N** |
|FISHER EXACT | P=0.753N P=0.753N | P=0.041N* P=0.007N** |
|=================================================================================================================================|
| |
|Mammary Gland |
| Fibroma, Fibroadenoma, Carcinoma, or Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 2/50 (4%) 3/50 (6%) 1/50 (2%) | 21/50 (42%) 14/50 (28%) 9/50 (18%) |
|ADJUSTED (b) | 19.3% 31.2% 7.7% | 57.5% 47.1% 42.1% |
|TERMINAL (d) | 1/7 (14%) 2/8 (25%) 0/4 (0%) | 13/27 (48%) 9/23 (39%) 4/15 (27%) |
|FIRST INCIDENCE (DAYS) | 682 722 684 | 425 542 648 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.541N P=0.579 P=0.603N | P=0.162N P=0.283N P=0.223N |
|INCIDENTAL TUMOR | P=0.507N P=0.579 P=0.579N | P=0.021N* P=0.065N P=0.032N* |
|LOGISTIC REGRESSION | P=0.495N P=0.616 P=0.571N | P=0.021N* P=0.147N P=0.027N* |
|COCHRAN-ARMITAGE | P=0.399N | P=0.006N** |
|FISHER EXACT | P=0.500 P=0.500N | P=0.104N P=0.008N** |
|=================================================================================================================================|
DATE: 09/06/94 EXPERIMENT: 05044 TEST: 01 PAGE 7
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN RATS(FISCHER344) -- 4-VINYL-1-CYCLOHEXENE DIEPOXIDE
TERMINAL SACRIFICE AT 107 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | 0 MG/ML 50 MG/ML 100 MG/ | 0 MG/ML 50 MG/ML 100 MG/ |
| | ML | ML |
|=================================================================================================================================|
| |
|Oral Cavity (Oral Mucosa, Tongue, Pharynx, Tooth, Lip) |
| Squamous Cell Carcinoma, Papilloma Squamous, or Papilloma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 1/50 (2%) 1/50 (2%) 0/50 (0%) | 1/50 (2%) 2/50 (4%) 1/50 (2%) |
|ADJUSTED (b) | 2.9% 4.5% 0.0% | 2.1% 6.3% 3.0% |
|TERMINAL (d) | 0/7 (0%) 0/8 (0%) 0/4 (0%) | 0/27 (0%) 1/23 (4%) 0/15 (0%) |
|FIRST INCIDENCE (DAYS) | 584 676 --- | 586 471 635 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.349N P=0.729N P=0.494N | P=0.538 P=0.468 P=0.712 |
|INCIDENTAL TUMOR | P=0.300N P=0.740 P=0.431N | P=0.523N P=0.668 P=0.710N |
|LOGISTIC REGRESSION | P=0.333N P=0.762N P=0.490N | P=0.576N P=0.549 P=0.729N |
|COCHRAN-ARMITAGE | P=0.331N | P=0.622N |
|FISHER EXACT | P=0.753N P=0.500N | P=0.500 P=0.753N |
|=================================================================================================================================|
| |
|Parathyroid Gland |
| Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 0/49 (0%) 2/45 (4%) 1/45 (2%) | 1/47 (2%) 1/43 (2%) 0/48 (0%) |
|ADJUSTED (b) | 0.0% 19.6% 25.0% | 2.6% 4.2% 0.0% |
|TERMINAL (d) | 0/7 (0%) 1/7 (14%) 1/4 (25%) | 0/26 (0%) 0/21 (0%) 0/14 (0%) |
|FIRST INCIDENCE (DAYS) | --- 695 743 (T) | 662 739 --- |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.222 P=0.271 P=0.388 | P=0.434N P=0.706 P=0.573N |
|INCIDENTAL TUMOR | P=0.251 P=0.264 P=0.388 | P=0.312N P=0.582 P=0.471N |
|LOGISTIC REGRESSION | P=0.247 P=0.270 P=0.388 | P=0.372N P=0.731 P=0.492N |
|COCHRAN-ARMITAGE | P=0.339 | P=0.329N |
|FISHER EXACT | P=0.226 P=0.479 | P=0.730 P=0.495N |
|=================================================================================================================================|
DATE: 09/06/94 EXPERIMENT: 05044 TEST: 01 PAGE 8
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN RATS(FISCHER344) -- 4-VINYL-1-CYCLOHEXENE DIEPOXIDE
TERMINAL SACRIFICE AT 107 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | 0 MG/ML 50 MG/ML 100 MG/ | 0 MG/ML 50 MG/ML 100 MG/ |
| | ML | ML |
|=================================================================================================================================|
| |
|Pituitary Gland: Pars Distalis or Unspecified Site |
| Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 24/50 (48%) 26/50 (52%) 27/48 (56%) | 19/47 (40%) 14/49 (29%) 17/48 (35%) |
|ADJUSTED (b) | 74.8% 89.8% 90.4% | 55.9% 43.0% 67.6% |
|TERMINAL (d) | 3/7 (43%) 6/8 (75%) 2/4 (50%) | 12/26 (46%) 7/23 (30%) 8/15 (53%) |
|FIRST INCIDENCE (DAYS) | 458 389 394 | 586 534 519 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.167 P=0.453N P=0.223 | P=0.153 P=0.382N P=0.116 |
|INCIDENTAL TUMOR | P=0.155 P=0.357 P=0.229 | P=0.486N P=0.174N P=0.571 |
|LOGISTIC REGRESSION | P=0.226 P=0.422 P=0.261 | P=0.514 P=0.230N P=0.471 |
|COCHRAN-ARMITAGE | P=0.237 | P=0.345N |
|FISHER EXACT | P=0.421 P=0.269 | P=0.157N P=0.385N |
|=================================================================================================================================|
| |
|Pituitary Gland: Pars Distalis or Unspecified Site |
| Carcinoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 2/50 (4%) 1/50 (2%) 0/48 (0%) | 14/47 (30%) 15/49 (31%) 11/48 (23%) |
|ADJUSTED (b) | 28.6% 2.8% 0.0% | 40.4% 46.9% 34.6% |
|TERMINAL (d) | 2/7 (29%) 0/8 (0%) 0/4 (0%) | 7/26 (27%) 7/23 (30%) 2/15 (13%) |
|FIRST INCIDENCE (DAYS) | 743 (T) 596 --- | 626 584 396 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.183N P=0.455N P=0.362N | P=0.323 P=0.275 P=0.375 |
|INCIDENTAL TUMOR | P=0.167N P=0.519N P=0.362N | P=0.230N P=0.285 P=0.200N |
|LOGISTIC REGRESSION | P=0.151N P=0.448N P=0.362N | P=0.317N P=0.304 P=0.302N |
|COCHRAN-ARMITAGE | P=0.148N | P=0.262N |
|FISHER EXACT | P=0.500N P=0.258N | P=0.554 P=0.299N |
|=================================================================================================================================|
DATE: 09/06/94 EXPERIMENT: 05044 TEST: 01 PAGE 9
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN RATS(FISCHER344) -- 4-VINYL-1-CYCLOHEXENE DIEPOXIDE
TERMINAL SACRIFICE AT 107 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | 0 MG/ML 50 MG/ML 100 MG/ | 0 MG/ML 50 MG/ML 100 MG/ |
| | ML | ML |
|=================================================================================================================================|
| |
|Pituitary Gland: Pars Distalis or Unspecified Site |
| Carcinoma or Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 26/50 (52%) 27/50 (54%) 27/48 (56%) | 33/47 (70%) 29/49 (59%) 28/48 (58%) |
|ADJUSTED (b) | 87.4% 90.1% 90.4% | 82.0% 75.5% 82.6% |
|TERMINAL (d) | 5/7 (71%) 6/8 (75%) 2/4 (50%) | 19/26 (73%) 14/23 (61%) 10/15 (67%) |
|FIRST INCIDENCE (DAYS) | 458 389 394 | 586 534 396 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.240 P=0.383N P=0.290 | P=0.107 P=0.471 P=0.086 |
|INCIDENTAL TUMOR | P=0.258 P=0.426 P=0.328 | P=0.194N P=0.423N P=0.226N |
|LOGISTIC REGRESSION | P=0.358 P=0.502 P=0.397 | P=0.320N P=0.341N P=0.360N |
|COCHRAN-ARMITAGE | P=0.374 | P=0.139N |
|FISHER EXACT | P=0.500 P=0.413 | P=0.180N P=0.160N |
|=================================================================================================================================|
| |
|Skin |
| Basal Cell Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 1/50 (2%) 0/50 (0%) 4/50 (8%) | 1/50 (2%) 1/50 (2%) 0/50 (0%) |
|ADJUSTED (b) | 4.2% 0.0% 42.5% | 3.7% 4.3% 0.0% |
|TERMINAL (d) | 0/7 (0%) 0/8 (0%) 1/4 (25%) | 1/27 (4%) 1/23 (4%) 0/15 (0%) |
|FIRST INCIDENCE (DAYS) | 620 --- 668 | 743 (T) 743 (T) --- |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.044 * P=0.443N P=0.118 | P=0.453N P=0.726 P=0.617N |
|INCIDENTAL TUMOR | P=0.070 P=0.587N P=0.155 | P=0.453N P=0.726 P=0.617N |
|LOGISTIC REGRESSION | P=0.063 P=0.500N P=0.143 | P=0.453N P=0.726 P=0.617N |
|COCHRAN-ARMITAGE | P=0.082 | P=0.331N |
|FISHER EXACT | P=0.500N P=0.181 | P=0.753N P=0.500N |
|=================================================================================================================================|
DATE: 09/06/94 EXPERIMENT: 05044 TEST: 01 PAGE 10
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN RATS(FISCHER344) -- 4-VINYL-1-CYCLOHEXENE DIEPOXIDE
TERMINAL SACRIFICE AT 107 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | 0 MG/ML 50 MG/ML 100 MG/ | 0 MG/ML 50 MG/ML 100 MG/ |
| | ML | ML |
|=================================================================================================================================|
| |
|Skin |
| Basal Cell Carcinoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 1/50 (2%) 2/50 (4%) 3/50 (6%) | 0/50 (0%) 3/50 (6%) 4/50 (8%) |
|ADJUSTED (b) | 3.8% 8.4% 20.1% | 0.0% 12.5% 20.0% |
|TERMINAL (d) | 0/7 (0%) 0/8 (0%) 0/4 (0%) | 0/27 (0%) 2/23 (9%) 2/15 (13%) |
|FIRST INCIDENCE (DAYS) | 619 642 595 | --- 739 654 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.170 P=0.597 P=0.266 | P=0.012 * P=0.098 P=0.020 * |
|INCIDENTAL TUMOR | P=0.281 P=0.425 P=0.356 | P=0.032 * P=0.066 P=0.040 * |
|LOGISTIC REGRESSION | P=0.208 P=0.508 P=0.291 | P=0.015 * P=0.081 P=0.032 * |
|COCHRAN-ARMITAGE | P=0.222 | P=0.049 * |
|FISHER EXACT | P=0.500 P=0.309 | P=0.121 P=0.059 |
|=================================================================================================================================|
| |
|Skin |
| Keratoacanthoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 0/50 (0%) 2/50 (4%) 3/50 (6%) | 0/50 (0%) 0/50 (0%) 0/50 (0%) |
|ADJUSTED (b) | 0.0% 8.6% 29.4% | 0.0% 0.0% 0.0% |
|TERMINAL (d) | 0/7 (0%) 0/8 (0%) 1/4 (25%) | 0/27 (0%) 0/23 (0%) 0/15 (0%) |
|FIRST INCIDENCE (DAYS) | --- 647 558 | --- --- --- |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.055 P=0.305 P=0.101 | (e) (e) (e) |
|INCIDENTAL TUMOR | P=0.089 P=0.287 P=0.125 | (e) (e) (e) |
|LOGISTIC REGRESSION | P=0.075 P=0.250 P=0.116 | (e) (e) (e) |
|COCHRAN-ARMITAGE | P=0.082 | (e) |
|FISHER EXACT | P=0.247 P=0.121 | (e) (e) |
|=================================================================================================================================|
DATE: 09/06/94 EXPERIMENT: 05044 TEST: 01 PAGE 11
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN RATS(FISCHER344) -- 4-VINYL-1-CYCLOHEXENE DIEPOXIDE
TERMINAL SACRIFICE AT 107 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | 0 MG/ML 50 MG/ML 100 MG/ | 0 MG/ML 50 MG/ML 100 MG/ |
| | ML | ML |
|=================================================================================================================================|
| |
|Skin |
| Squamous Cell Carcinoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 0/50 (0%) 33/50 (66%) 36/50 (72%) | 0/50 (0%) 16/50 (32%) 34/50 (68%) |
|ADJUSTED (b) | 0.0% 100.0% 100.0% | 0.0% 63.6% 100.0% |
|TERMINAL (d) | 0/7 (0%) 8/8 (100%) 4/4 (100%) | 0/27 (0%) 14/23 (61%) 15/15 (100%) |
|FIRST INCIDENCE (DAYS) | --- 596 543 | --- 625 601 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P<0.001 ** P<0.001 ** P<0.001 ** | P<0.001 ** P<0.001 ** P<0.001 ** |
|INCIDENTAL TUMOR | P<0.001 ** P<0.001 ** P<0.001 ** | P<0.001 ** P<0.001 ** P<0.001 ** |
|LOGISTIC REGRESSION | P<0.001 ** P<0.001 ** P<0.001 ** | P<0.001 ** P<0.001 ** P<0.001 ** |
|COCHRAN-ARMITAGE | P<0.001 ** | P<0.001 ** |
|FISHER EXACT | P<0.001 ** P<0.001 ** | P<0.001 ** P<0.001 ** |
|=================================================================================================================================|
| |
|Skin |
| Squamous Cell Carcinoma, Papilloma Squamous, or Papilloma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 0/50 (0%) 33/50 (66%) 36/50 (72%) | 0/50 (0%) 16/50 (32%) 34/50 (68%) |
|ADJUSTED (b) | 0.0% 100.0% 100.0% | 0.0% 63.6% 100.0% |
|TERMINAL (d) | 0/7 (0%) 8/8 (100%) 4/4 (100%) | 0/27 (0%) 14/23 (61%) 15/15 (100%) |
|FIRST INCIDENCE (DAYS) | --- 596 543 | --- 625 601 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P<0.001 ** P<0.001 ** P<0.001 ** | P<0.001 ** P<0.001 ** P<0.001 ** |
|INCIDENTAL TUMOR | P<0.001 ** P<0.001 ** P<0.001 ** | P<0.001 ** P<0.001 ** P<0.001 ** |
|LOGISTIC REGRESSION | P<0.001 ** P<0.001 ** P<0.001 ** | P<0.001 ** P<0.001 ** P<0.001 ** |
|COCHRAN-ARMITAGE | P<0.001 ** | P<0.001 ** |
|FISHER EXACT | P<0.001 ** P<0.001 ** | P<0.001 ** P<0.001 ** |
|=================================================================================================================================|
DATE: 09/06/94 EXPERIMENT: 05044 TEST: 01 PAGE 12
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN RATS(FISCHER344) -- 4-VINYL-1-CYCLOHEXENE DIEPOXIDE
TERMINAL SACRIFICE AT 107 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | 0 MG/ML 50 MG/ML 100 MG/ | 0 MG/ML 50 MG/ML 100 MG/ |
| | ML | ML |
|=================================================================================================================================|
| |
|Skin |
| Squamous Cell Papilloma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 0/50 (0%) 3/50 (6%) 6/50 (12%) | 0/50 (0%) 0/50 (0%) 1/50 (2%) |
|ADJUSTED (b) | 0.0% 25.2% 39.3% | 0.0% 0.0% 4.5% |
|TERMINAL (d) | 0/7 (0%) 1/8 (13%) 0/4 (0%) | 0/27 (0%) 0/23 (0%) 0/15 (0%) |
|FIRST INCIDENCE (DAYS) | --- 688 595 | --- --- 689 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.004 ** P=0.174 P=0.014 * | P=0.204 (e) P=0.396 |
|INCIDENTAL TUMOR | P=0.012 * P=0.158 P=0.026 * | P=0.324 (e) P=0.541 |
|LOGISTIC REGRESSION | P=0.006 ** P=0.159 P=0.015 * | P=0.248 (e) P=0.476 |
|COCHRAN-ARMITAGE | P=0.010 * | P=0.269 |
|FISHER EXACT | P=0.121 P=0.013 * | (e) P=0.500 |
|=================================================================================================================================|
| |
|Skin |
| Trichoepithelioma, Basal Cell Carcinoma, or Basal Cell Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 2/50 (4%) 2/50 (4%) 7/50 (14%) | 1/50 (2%) 4/50 (8%) 4/50 (8%) |
|ADJUSTED (b) | 7.9% 8.4% 51.2% | 3.7% 16.7% 20.0% |
|TERMINAL (d) | 0/7 (0%) 0/8 (0%) 1/4 (25%) | 1/27 (4%) 3/23 (13%) 2/15 (13%) |
|FIRST INCIDENCE (DAYS) | 619 642 595 | 743 (T) 739 654 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.022 * P=0.587N P=0.055 | P=0.040 * P=0.137 P=0.064 |
|INCIDENTAL TUMOR | P=0.060 P=0.597 P=0.096 | P=0.080 P=0.105 P=0.106 |
|LOGISTIC REGRESSION | P=0.034 * P=0.691N P=0.066 | P=0.047 * P=0.119 P=0.091 |
|COCHRAN-ARMITAGE | P=0.042 * | P=0.146 |
|FISHER EXACT | P=0.691N P=0.080 | P=0.181 P=0.181 |
|=================================================================================================================================|
DATE: 09/06/94 EXPERIMENT: 05044 TEST: 01 PAGE 13
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN RATS(FISCHER344) -- 4-VINYL-1-CYCLOHEXENE DIEPOXIDE
TERMINAL SACRIFICE AT 107 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | 0 MG/ML 50 MG/ML 100 MG/ | 0 MG/ML 50 MG/ML 100 MG/ |
| | ML | ML |
|=================================================================================================================================|
| |
|Skin |
| Trichoepithelioma, Kertatocanthoma, Squamous Cell Carcinoma, |
| Basal Cell Carcinoma or Adenoma, Papilloma Squamous, or Papilloma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 2/50 (4%) 33/50 (66%) 37/50 (74%) | 1/50 (2%) 17/50 (34%) 34/50 (68%) |
|ADJUSTED (b) | 7.9% 100.0% 100.0% | 3.7% 65.1% 100.0% |
|TERMINAL (d) | 0/7 (0%) 8/8 (100%) 4/4 (100%) | 1/27 (4%) 14/23 (61%) 15/15 (100%) |
|FIRST INCIDENCE (DAYS) | 619 596 543 | 743 (T) 625 601 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P<0.001 ** P<0.001 ** P<0.001 ** | P<0.001 ** P<0.001 ** P<0.001 ** |
|INCIDENTAL TUMOR | P<0.001 ** P<0.001 ** P<0.001 ** | P<0.001 ** P<0.001 ** P<0.001 ** |
|LOGISTIC REGRESSION | P<0.001 ** P<0.001 ** P<0.001 ** | P<0.001 ** P<0.001 ** P<0.001 ** |
|COCHRAN-ARMITAGE | P<0.001 ** | P<0.001 ** |
|FISHER EXACT | P<0.001 ** P<0.001 ** | P<0.001 ** P<0.001 ** |
|=================================================================================================================================|
| |
|Skin: Subcutaneous Tissue |
| Fibroma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 1/50 (2%) 2/50 (4%) 0/50 (0%) | 2/50 (4%) 0/50 (0%) 0/50 (0%) |
|ADJUSTED (b) | 14.3% 15.4% 0.0% | 6.1% 0.0% 0.0% |
|TERMINAL (d) | 1/7 (14%) 1/8 (13%) 0/4 (0%) | 1/27 (4%) 0/23 (0%) 0/15 (0%) |
|FIRST INCIDENCE (DAYS) | 743 (T) 642 --- | 635 --- --- |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.455N P=0.563 P=0.612N | P=0.140N P=0.289N P=0.330N |
|INCIDENTAL TUMOR | P=0.407N P=0.481 P=0.612N | P=0.097N P=0.173N P=0.271N |
|LOGISTIC REGRESSION | P=0.404N P=0.571 P=0.612N | P=0.104N P=0.245N P=0.256N |
|COCHRAN-ARMITAGE | P=0.360N | P=0.095N |
|FISHER EXACT | P=0.500 P=0.500N | P=0.247N P=0.247N |
|=================================================================================================================================|
DATE: 09/06/94 EXPERIMENT: 05044 TEST: 01 PAGE 14
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN RATS(FISCHER344) -- 4-VINYL-1-CYCLOHEXENE DIEPOXIDE
TERMINAL SACRIFICE AT 107 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | 0 MG/ML 50 MG/ML 100 MG/ | 0 MG/ML 50 MG/ML 100 MG/ |
| | ML | ML |
|=================================================================================================================================|
| |
|Skin: Subcutaneous Tissue |
| Neurofibrosarcoma, Fibrosarcoma, Sarcoma, |
| Neurofibroma, or Fibroma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 2/50 (4%) 2/50 (4%) 1/50 (2%) | 2/50 (4%) 0/50 (0%) 0/50 (0%) |
|ADJUSTED (b) | 16.4% 15.4% 25.0% | 6.1% 0.0% 0.0% |
|TERMINAL (d) | 1/7 (14%) 1/8 (13%) 1/4 (25%) | 1/27 (4%) 0/23 (0%) 0/15 (0%) |
|FIRST INCIDENCE (DAYS) | 548 642 743 (T) | 635 --- --- |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.498N P=0.649N P=0.622N | P=0.140N P=0.289N P=0.330N |
|INCIDENTAL TUMOR | P=0.432N P=0.643 P=0.591N | P=0.097N P=0.173N P=0.271N |
|LOGISTIC REGRESSION | P=0.420N P=0.674N P=0.536N | P=0.104N P=0.245N P=0.256N |
|COCHRAN-ARMITAGE | P=0.390N | P=0.095N |
|FISHER EXACT | P=0.691N P=0.500N | P=0.247N P=0.247N |
|=================================================================================================================================|
| |
|Testes |
| Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 44/50 (88%) 40/50 (80%) 39/50 (78%) | |
|ADJUSTED (b) | 100.0% 100.0% 100.0% | |
|TERMINAL (d) | 7/7 (100%) 8/8 (100%) 4/4 (100%) | |
|FIRST INCIDENCE (DAYS) | 379 387 543 | |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.430 P=0.116N P=0.449 | |
|INCIDENTAL TUMOR | P=0.149N P=0.211N P=0.162N | |
|LOGISTIC REGRESSION | P=0.139N P=0.248N P=0.143N | |
|COCHRAN-ARMITAGE | P=0.121N | |
|FISHER EXACT | P=0.207N P=0.143N | |
|=================================================================================================================================|
DATE: 09/06/94 EXPERIMENT: 05044 TEST: 01 PAGE 15
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN RATS(FISCHER344) -- 4-VINYL-1-CYCLOHEXENE DIEPOXIDE
TERMINAL SACRIFICE AT 107 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | 0 MG/ML 50 MG/ML 100 MG/ | 0 MG/ML 50 MG/ML 100 MG/ |
| | ML | ML |
|=================================================================================================================================|
| |
|Thyroid Gland: C-Cell |
| Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 7/48 (15%) 6/50 (12%) 2/43 (5%) | 6/46 (13%) 14/48 (29%) 9/49 (18%) |
|ADJUSTED (b) | 39.0% 22.4% 27.3% | 21.4% 45.8% 39.0% |
|TERMINAL (d) | 1/7 (14%) 0/8 (0%) 1/4 (25%) | 5/27 (19%) 8/23 (35%) 4/15 (27%) |
|FIRST INCIDENCE (DAYS) | 379 538 595 | 736 471 404 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.122N P=0.388N P=0.174N | P=0.040 * P=0.018 * P=0.053 |
|INCIDENTAL TUMOR | P=0.121N P=0.373N P=0.199N | P=0.224 P=0.022 * P=0.202 |
|LOGISTIC REGRESSION | P=0.089N P=0.468N P=0.108N | P=0.208 P=0.027 * P=0.223 |
|COCHRAN-ARMITAGE | P=0.088N | P=0.315 |
|FISHER EXACT | P=0.468N P=0.108N | P=0.048 * P=0.335 |
|=================================================================================================================================|
| |
|Thyroid Gland: C-Cell |
| Carcinoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 2/48 (4%) 0/50 (0%) 0/43 (0%) | 0/46 (0%) 3/48 (6%) 1/49 (2%) |
|ADJUSTED (b) | 9.1% 0.0% 0.0% | 0.0% 8.7% 6.7% |
|TERMINAL (d) | 0/7 (0%) 0/8 (0%) 0/4 (0%) | 0/27 (0%) 1/23 (4%) 1/15 (7%) |
|FIRST INCIDENCE (DAYS) | 607 --- --- | --- 542 743 (T) |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.096N P=0.202N P=0.261N | P=0.268 P=0.106 P=0.383 |
|INCIDENTAL TUMOR | P=0.096N P=0.260N P=0.236N | P=0.414 P=0.216 P=0.383 |
|LOGISTIC REGRESSION | P=0.102N P=0.227N P=0.263N | P=0.411 P=0.144 P=0.383 |
|COCHRAN-ARMITAGE | P=0.102N | P=0.398 |
|FISHER EXACT | P=0.237N P=0.275N | P=0.129 P=0.516 |
|=================================================================================================================================|
DATE: 09/06/94 EXPERIMENT: 05044 TEST: 01 PAGE 16
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN RATS(FISCHER344) -- 4-VINYL-1-CYCLOHEXENE DIEPOXIDE
TERMINAL SACRIFICE AT 107 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | 0 MG/ML 50 MG/ML 100 MG/ | 0 MG/ML 50 MG/ML 100 MG/ |
| | ML | ML |
|=================================================================================================================================|
| |
|Thyroid Gland: C-Cell |
| Carcinoma or Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 9/48 (19%) 6/50 (12%) 2/43 (5%) | 6/46 (13%) 15/48 (31%) 10/49 (20%) |
|ADJUSTED (b) | 44.6% 22.4% 27.3% | 21.4% 49.4% 44.5% |
|TERMINAL (d) | 1/7 (14%) 0/8 (0%) 1/4 (25%) | 5/27 (19%) 9/23 (39%) 5/15 (33%) |
|FIRST INCIDENCE (DAYS) | 379 538 595 | 736 471 404 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.044N* P=0.203N P=0.076N | P=0.020 * P=0.010 ** P=0.026 * |
|INCIDENTAL TUMOR | P=0.039N* P=0.199N P=0.077N | P=0.136 P=0.012 * P=0.118 |
|LOGISTIC REGRESSION | P=0.029N* P=0.259N P=0.041N* | P=0.131 P=0.015 * P=0.137 |
|COCHRAN-ARMITAGE | P=0.029N* | P=0.239 |
|FISHER EXACT | P=0.259N P=0.038N* | P=0.030 * P=0.248 |
|=================================================================================================================================|
| |
|Thyroid Gland: Follicular Cell |
| Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 1/48 (2%) 3/50 (6%) 3/43 (7%) | 2/46 (4%) 0/48 (0%) 1/49 (2%) |
|ADJUSTED (b) | 4.5% 19.2% 29.7% | 7.4% 0.0% 3.7% |
|TERMINAL (d) | 0/7 (0%) 1/8 (13%) 1/4 (25%) | 2/27 (7%) 0/23 (0%) 0/15 (0%) |
|FIRST INCIDENCE (DAYS) | 667 569 503 | 743 (T) --- 670 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.161 P=0.374 P=0.236 | P=0.497N P=0.274N P=0.672N |
|INCIDENTAL TUMOR | P=0.171 P=0.319 P=0.207 | P=0.411N P=0.274N P=0.582N |
|LOGISTIC REGRESSION | P=0.197 P=0.333 P=0.265 | P=0.440N P=0.274N P=0.605N |
|COCHRAN-ARMITAGE | P=0.199 | P=0.343N |
|FISHER EXACT | P=0.324 P=0.268 | P=0.237N P=0.476N |
|=================================================================================================================================|
DATE: 09/06/94 EXPERIMENT: 05044 TEST: 01 PAGE 17
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN RATS(FISCHER344) -- 4-VINYL-1-CYCLOHEXENE DIEPOXIDE
TERMINAL SACRIFICE AT 107 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | 0 MG/ML 50 MG/ML 100 MG/ | 0 MG/ML 50 MG/ML 100 MG/ |
| | ML | ML |
|=================================================================================================================================|
| |
|Thyroid Gland: Follicular Cell |
| Carcinoma or Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 2/48 (4%) 4/50 (8%) 3/43 (7%) | 2/46 (4%) 0/48 (0%) 1/49 (2%) |
|ADJUSTED (b) | 7.1% 27.3% 29.7% | 7.4% 0.0% 3.7% |
|TERMINAL (d) | 0/7 (0%) 1/8 (13%) 1/4 (25%) | 2/27 (7%) 0/23 (0%) 0/15 (0%) |
|FIRST INCIDENCE (DAYS) | 571 569 503 | 743 (T) --- 670 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.312 P=0.417 P=0.425 | P=0.497N P=0.274N P=0.672N |
|INCIDENTAL TUMOR | P=0.346 P=0.332 P=0.407 | P=0.411N P=0.274N P=0.582N |
|LOGISTIC REGRESSION | P=0.359 P=0.369 P=0.450 | P=0.440N P=0.274N P=0.605N |
|COCHRAN-ARMITAGE | P=0.363 | P=0.343N |
|FISHER EXACT | P=0.359 P=0.447 | P=0.237N P=0.476N |
|=================================================================================================================================|
| |
|Urinary Bladder |
| Papilloma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 0/49 (0%) 0/50 (0%) 0/49 (0%) | 0/50 (0%) 2/50 (4%) 0/48 (0%) |
|ADJUSTED (b) | 0.0% 0.0% 0.0% | 0.0% 8.0% 0.0% |
|TERMINAL (d) | 0/6 (0%) 0/8 (0%) 0/4 (0%) | 0/27 (0%) 1/23 (4%) 0/14 (0%) |
|FIRST INCIDENCE (DAYS) | --- --- --- | --- 676 --- |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | (e) (e) (e) | P=0.553 P=0.183 (e) |
|INCIDENTAL TUMOR | (e) (e) (e) | P=0.626 P=0.144 (e) |
|LOGISTIC REGRESSION | (e) (e) (e) | P=0.602 P=0.205 (e) |
|COCHRAN-ARMITAGE | (e) | P=0.661 |
|FISHER EXACT | (e) (e) | P=0.247 (e) |
|=================================================================================================================================|
DATE: 09/06/94 EXPERIMENT: 05044 TEST: 01 PAGE 18
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN RATS(FISCHER344) -- 4-VINYL-1-CYCLOHEXENE DIEPOXIDE
TERMINAL SACRIFICE AT 107 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | 0 MG/ML 50 MG/ML 100 MG/ | 0 MG/ML 50 MG/ML 100 MG/ |
| | ML | ML |
|=================================================================================================================================|
| |
|Uterus |
| Polyp Stromal |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | # # # |
|----------- | | |
|OVERALL (a) | | 3/50 (6%) 8/50 (16%) 6/50 (12%) |
|ADJUSTED (b) | | 7.8% 30.8% 26.2% |
|TERMINAL (d) | | 0/27 (0%) 6/23 (26%) 2/15 (13%) |
|FIRST INCIDENCE (DAYS) | | 626 600 404 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | | P=0.044 * P=0.053 P=0.070 |
|INCIDENTAL TUMOR | | P=0.215 P=0.056 P=0.398 |
|LOGISTIC REGRESSION | | P=0.163 P=0.060 P=0.272 |
|COCHRAN-ARMITAGE | | P=0.215 |
|FISHER EXACT | | P=0.100 P=0.243 |
|=================================================================================================================================|
| |
|Uterus |
| Sarcoma Stromal or Polyp Stromal |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | # # # |
|----------- | | |
|OVERALL (a) | | 3/50 (6%) 9/50 (18%) 6/50 (12%) |
|ADJUSTED (b) | | 7.8% 32.3% 26.2% |
|TERMINAL (d) | | 0/27 (0%) 6/23 (26%) 2/15 (13%) |
|FIRST INCIDENCE (DAYS) | | 626 534 404 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | | P=0.048 * P=0.032 * P=0.070 |
|INCIDENTAL TUMOR | | P=0.265 P=0.044 * P=0.398 |
|LOGISTIC REGRESSION | | P=0.189 P=0.045 * P=0.272 |
|COCHRAN-ARMITAGE | | P=0.221 |
|FISHER EXACT | | P=0.061 P=0.243 |
|=================================================================================================================================|
DATE: 09/06/94 EXPERIMENT: 05044 TEST: 01 PAGE 19
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN RATS(FISCHER344) -- 4-VINYL-1-CYCLOHEXENE DIEPOXIDE
TERMINAL SACRIFICE AT 107 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | 0 MG/ML 50 MG/ML 100 MG/ | 0 MG/ML 50 MG/ML 100 MG/ |
| | ML | ML |
|=================================================================================================================================|
| |
|Zymbal's Gland |
| Carcinoma or Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 0/50 (0%) 0/50 (0%) 2/50 (4%) | 0/50 (0%) 0/50 (0%) 0/50 (0%) |
|ADJUSTED (b) | 0.0% 0.0% 6.2% | 0.0% 0.0% 0.0% |
|TERMINAL (d) | 0/7 (0%) 0/8 (0%) 0/4 (0%) | 0/27 (0%) 0/23 (0%) 0/15 (0%) |
|FIRST INCIDENCE (DAYS) | --- --- 591 | --- --- --- |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.100 (e) P=0.258 | (e) (e) (e) |
|INCIDENTAL TUMOR | P=0.158 (e) P=0.316 | (e) (e) (e) |
|LOGISTIC REGRESSION | P=0.097 (e) P=0.242 | (e) (e) (e) |
|COCHRAN-ARMITAGE | P=0.095 | (e) |
|FISHER EXACT | (e) P=0.247 | (e) (e) |
|=================================================================================================================================|
| |
|All Organs |
| Leukemia: Lymphocytic, Monocytic, Mononuclear, |
| or Undifferentiated |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 16/50 (32%) 15/50 (30%) 15/50 (30%) | 12/50 (24%) 17/50 (34%) 13/50 (26%) |
|ADJUSTED (b) | 60.3% 65.7% 70.3% | 31.1% 58.7% 50.9% |
|TERMINAL (d) | 2/7 (29%) 3/8 (38%) 1/4 (25%) | 2/27 (7%) 12/23 (52%) 5/15 (33%) |
|FIRST INCIDENCE (DAYS) | 379 404 543 | 586 571 601 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.428 P=0.322N P=0.488 | P=0.064 P=0.081 P=0.089 |
|INCIDENTAL TUMOR | P=0.500N P=0.495N P=0.525N | P=0.304 P=0.073 P=0.497 |
|LOGISTIC REGRESSION | P=0.483N P=0.495N P=0.519N | P=0.226 P=0.103 P=0.324 |
|COCHRAN-ARMITAGE | P=0.457N | P=0.456 |
|FISHER EXACT | P=0.500N P=0.500N | P=0.189 P=0.500 |
|=================================================================================================================================|
DATE: 09/06/94 EXPERIMENT: 05044 TEST: 01 PAGE 20
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN RATS(FISCHER344) -- 4-VINYL-1-CYCLOHEXENE DIEPOXIDE
TERMINAL SACRIFICE AT 107 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | 0 MG/ML 50 MG/ML 100 MG/ | 0 MG/ML 50 MG/ML 100 MG/ |
| | ML | ML |
|=================================================================================================================================|
| |
|All Organs |
| Mesothelioma Benign, Malignant, NOS |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 1/50 (2%) 2/50 (4%) 1/50 (2%) | 0/50 (0%) 0/50 (0%) 0/50 (0%) |
|ADJUSTED (b) | 2.1% 8.2% 2.4% | 0.0% 0.0% 0.0% |
|TERMINAL (d) | 0/7 (0%) 0/8 (0%) 0/4 (0%) | 0/27 (0%) 0/23 (0%) 0/15 (0%) |
|FIRST INCIDENCE (DAYS) | 470 626 550 | --- --- --- |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.610 P=0.571 P=0.752N | (e) (e) (e) |
|INCIDENTAL TUMOR | P=0.608N P=0.476 P=0.730 | (e) (e) (e) |
|LOGISTIC REGRESSION | P=0.611N P=0.507 P=0.714N | (e) (e) (e) |
|COCHRAN-ARMITAGE | P=0.622N | (e) |
|FISHER EXACT | P=0.500 P=0.753N | (e) (e) |
|=================================================================================================================================|
| |
|All Organs |
| Benign Tumors |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 50/50 (100%) 45/50 (90%) 46/50 (92%) | 39/50 (78%) 40/50 (80%) 32/50 (64%) |
|ADJUSTED (b) | 100.0% 100.0% 100.0% | 88.2% 95.1% 88.4% |
|TERMINAL (d) | 7/7 (100%) 8/8 (100%) 4/4 (100%) | 22/27 (81%) 21/23 (91%) 11/15 (73%) |
|FIRST INCIDENCE (DAYS) | 379 387 394 | 425 471 404 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.378 P=0.101N P=0.411 | P=0.078 P=0.130 P=0.083 |
|INCIDENTAL TUMOR | P=0.191N P=0.038N* P=0.197N | P=0.180N P=0.388 P=0.231N |
|LOGISTIC REGRESSION | P=0.093N P=0.072N P=0.116N | P=0.227N P=0.332 P=0.274N |
|COCHRAN-ARMITAGE | P=0.070N | P=0.069N |
|FISHER EXACT | P=0.028N* P=0.059N | P=0.500 P=0.093N |
|=================================================================================================================================|
DATE: 09/06/94 EXPERIMENT: 05044 TEST: 01 PAGE 21
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN RATS(FISCHER344) -- 4-VINYL-1-CYCLOHEXENE DIEPOXIDE
TERMINAL SACRIFICE AT 107 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | 0 MG/ML 50 MG/ML 100 MG/ | 0 MG/ML 50 MG/ML 100 MG/ |
| | ML | ML |
|=================================================================================================================================|
| |
|All Organs |
| Malignant Tumors |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 24/50 (48%) 40/50 (80%) 41/50 (82%) | 25/50 (50%) 38/50 (76%) 39/50 (78%) |
|ADJUSTED (b) | 75.9% 100.0% 100.0% | 61.8% 97.4% 100.0% |
|TERMINAL (d) | 3/7 (43%) 8/8 (100%) 4/4 (100%) | 12/27 (44%) 22/23 (96%) 15/15 (100%) |
|FIRST INCIDENCE (DAYS) | 379 373 242 | 586 534 396 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.001 ** P=0.105 P=0.004 ** | P<0.001 ** P=0.002 ** P<0.001 ** |
|INCIDENTAL TUMOR | P<0.001 ** P<0.001 ** P=0.002 ** | P<0.001 ** P<0.001 ** P<0.001 ** |
|LOGISTIC REGRESSION | P<0.001 ** P<0.001 ** P<0.001 ** | P<0.001 ** P<0.001 ** P<0.001 ** |
|COCHRAN-ARMITAGE | P<0.001 ** | P=0.002 ** |
|FISHER EXACT | P<0.001 ** P<0.001 ** | P=0.006 ** P=0.003 ** |
|=================================================================================================================================|
| |
|All Organs |
| Malignant and Benign Tumors |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 50/50 (100%) 49/50 (98%) 49/50 (98%) | 43/50 (86%) 47/50 (94%) 44/50 (88%) |
|ADJUSTED (b) | 100.0% 100.0% 100.0% | 89.6% 100.0% 100.0% |
|TERMINAL (d) | 7/7 (100%) 8/8 (100%) 4/4 (100%) | 22/27 (81%) 23/23 (100%) 15/15 (100%) |
|FIRST INCIDENCE (DAYS) | 379 373 242 | 425 471 396 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.261 P=0.210N P=0.295 | P=0.003 ** P=0.050 P=0.003 ** |
|INCIDENTAL TUMOR | P=0.485N (e) P=0.362N | P=0.207 P=0.059 P=0.339 |
|LOGISTIC REGRESSION | P=0.437N (e) P=0.626N | P=0.159 P=0.203 P=0.233 |
|COCHRAN-ARMITAGE | P=0.331N | P=0.436 |
|FISHER EXACT | P=0.500N P=0.500N | P=0.159 P=0.500 |
|=================================================================================================================================|
DATE: 09/06/94 EXPERIMENT: 05044 TEST: 01 PAGE 22
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN RATS(FISCHER344) -- 4-VINYL-1-CYCLOHEXENE DIEPOXIDE
TERMINAL SACRIFICE AT 107 WEEKS
(a) Number of tumor-bearing animals / number of animals examined at site.
(b) Kaplan-Meier estimated lifetime tumor incidence after adjustment for
intercurrent mortality.
(d) Observed incidence at terminal kill.
(f) Beneath the control incidence are the P-values associated with the trend
test. Beneath the dosed group incidence are the P-values corresponding to
pairwise comparisons between the controls and that dosed group. The life
table analysis regards tumors in animals dying prior to terminal kill as
being (directly or indirectly) the cause of death. The incidental tumor
test regards these lesions as non-fatal. Logistic regression is an alternative
method for analyzing the incidence of non-fatal tumors. The Cochran-Armitage
and Fisher's exact tests compare directly the overall incidence rates.
For all tests, a negative trend is indicated by "N".
(e) Value of Statistic cannot be computed.
(I) Interim sacrifice
(T) Terminal sacrifice
# Tumor rates based on number of animals necropsied.
* To the right of any statistical result, indicates significance at (P<=0.05).
** To the right of any statistical result, indicates significance at (P<=0.01).
--multipart-boundary
Content-type: text/plain
Range: bytes 149862-149862/149862
--multipart-boundary--